Titanium Dioxide Acetic Acid Citric Acid Sodium Hydroxide Oxalic Acid Ethyl Acetate

All Categories

Encyclopedia |

Market Inquiry|

Supplier|

About Xchemi

Tirzepatide

CAS No.: 2023788-19-2

Formula: -

Molecular Weight: 0

Suppliers: All(0) China Suppliers(47) Products(49)

Description
Basic Info
Safety Info
Price
Related Product
Supplier Reference

What is Tirzepatide

**Introduction to Tirzepatide** Tirzepatide is a groundbreaking dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, developed to manage type 2 diabetes and support weight loss. By mimicking the actions of both GIP and GLP-1 hormones, it enhances insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety. Clinical trials have demonstrated its efficacy in significantly lowering blood sugar levels and facilitating substantial weight reduction. Approved by the FDA under the brand name *Mounjaro* for diabetes and *Zepbound* for obesity, tirzepatide offers a promising therapeutic option for patients seeking improved glycemic control and sustainable weight management. Its innovative mechanism sets a new standard in metabolic care. (100 words)

Preparation Process: Tirzepatide is synthesized via solid-phase peptide synthesis (SPPS) using Fmoc chemistry. The linear peptide sequence (40 amino acids) is assembled on a resin, followed by sequential coupling of protected amino acids. After chain assembly, the peptide is cleaved from the resin using trifluoroacetic acid (TFA) and purified via reverse-phase HPLC. The C20 fatty diacid moiety is then conjugated to the lysine residue at position 20 using acylation chemistry. The final product undergoes further purification, lyophilization, and characterization by mass spectrometry and analytical HPLC to ensure purity (>95%) and correct structure. The compound is formulated as a sterile solution for injection.

Usage Scenarios: Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist used primarily to manage type 2 diabetes mellitus and chronic weight management in adults. It enhances insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety, improving glycemic control and aiding weight loss. Administered via weekly subcutaneous injections, tirzepatide has demonstrated superior efficacy in reducing HbA1c and body weight compared to other GLP-1 receptor agonists. Common side effects include gastrointestinal disturbances such as nausea, vomiting, and diarrhea. It is prescribed alongside diet and exercise for optimal therapeutic outcomes.

Tirzepatide Basic Info

Chemical Name Tirzepatide

Synonyms GLP-1 RA;Tilpotide;Tilposide;GIP\GLP-1;Tirzpatide;Tirzepatide;Trizepatide;terzapitide;tirzepatide 10mg;Tirzepatide(GLP-1)

CAS No. 2023788-19-2

Molecular Formula -

Molecular Weight 0

PSA -

LogP -

Safely Info

RTECS -

Hazard Class -

Safety Statements -

HS Code -

WGK Germany -

Packing Group -

RIDADR -

Risk Statements -

Hazard Codes -

Caution Statement -

Hazard Declaration H361d

Symbol GHS08

Signal Word Warning

Tirzepatide Price

Here is a rough price range for Tirzepatide (if available) in the listed countries. Note that prices can vary based on dosage, brand, and local market conditions:

1. **United States**: $800 - $1,200 per month
2. **China**: No results
3. **Russia**: No results
4. **Germany**: €700 - €1,000 per month
5. **India**: No results
6. **Japan**: ¥80,000 - ¥120,000 per month
7. **Brazil**: No results
8. **South Korea**: ₩900,000 - ₩1,300,000 per month
9. **Philippines**: No results
10. **United Kingdom**: £600 - £900 per month
11. **France**: €700 - €1,000 per month
12. **Mexico**: No results
13. **Canada**: CAD 900 - CAD 1,300 per month
14. **South Africa**: No results
15. **Egypt**: No results
16. **Turkey**: No results
17. **Thailand**: No results
18. **Indonesia**: No results

*Note: Tirzepatide is a prescription medication, and availability/pricing may vary significantly depending on local regulations, insurance coverage, and market access.*